BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 12094697)

  • 1. [Recent advances in the diagnosis and treatment of colorectal cancers].
    Mimori K; Mori M
    Nihon Geka Gakkai Zasshi; 2002 Jun; 103(6):468-71. PubMed ID: 12094697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Systemic chemotherapy of colorectal cancer--recent approaches].
    Furue H
    Gan To Kagaku Ryoho; 1991 Apr; 18(4):529-34. PubMed ID: 2012395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
    Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
    Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reproducibility of a multitarget stool-based DNA assay for colorectal cancer detection.
    Brand RE; Ross ME; Shuber AP
    Am J Gastroenterol; 2004 Jul; 99(7):1338-41. PubMed ID: 15233675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic and predictive relevance of microsatellite instability in colorectal cancer.
    Storojeva I; Boulay JL; Heinimann K; Ballabeni P; Terracciano L; Laffer U; Mild G; Herrmann R; Rochlitz C
    Oncol Rep; 2005 Jul; 14(1):241-9. PubMed ID: 15944796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limitations in molecular detection of lymph node micrometastasis from colorectal cancer.
    Klebig F; Fischer C; Petri S; Gerull H; Wagener C; Tschentscher P
    Diagn Mol Pathol; 2007 Jun; 16(2):91-5. PubMed ID: 17525678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model.
    Kim HS; Park HM; Park JS; Sohn HJ; Kim SG; Kim HJ; Oh ST; Kim TG
    Vaccine; 2010 Nov; 28(49):7787-96. PubMed ID: 20883737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active specific immunotherapy for colorectal cancer.
    Indar AA; Maxwell-Armstrong CA
    Expert Rev Anticancer Ther; 2003 Oct; 3(5):685-94. PubMed ID: 14599091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular stool screening for colorectal cancer.
    Mak T; Lalloo F; Evans DG; Hill J
    Br J Surg; 2004 Jul; 91(7):790-800. PubMed ID: 15227685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current concepts in the genetics of hereditary and sporadic colorectal cancer and the role of genetics in clinical practice: sporadic and IBD-associated colorectal tumors, significance of genetic tests in diagnosis, prognosis and assessment of chemotherapy outcome].
    Lakatos PL; Lakatos L
    Orv Hetil; 2006 Mar; 147(10):449-55. PubMed ID: 16573174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances of molecular biology in colorectal cancer.
    Baba S
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():336-44. PubMed ID: 10895177
    [No Abstract]   [Full Text] [Related]  

  • 12. [Genetic diagnosis of colorectal cancer].
    Itoh F; Imai K
    Hokkaido Igaku Zasshi; 1996 Jan; 71(1):9-14. PubMed ID: 8727369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies.
    Atreya I; Neurath MF
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):561-72. PubMed ID: 18402523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular detection of neoplastic cells in lymph nodes of metastatic colorectal cancer patients predicts recurrence.
    Sanchez-Cespedes M; Esteller M; Hibi K; Cope FO; Westra WH; Piantadosi S; Herman JG; Jen J; Sidransky D
    Clin Cancer Res; 1999 Sep; 5(9):2450-4. PubMed ID: 10499618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Advances in the treatment of colorectal cancer].
    Maehara Y; Ohno S; Tomisaki S; Kakeji Y; Watanabe A; Baba H; Adachi Y; Ichiyoshi Y; Korenaga D; Sugimachi K
    Gan To Kagaku Ryoho; 1996 Apr; 23(5):517-28. PubMed ID: 8678508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoresponsiveness associated with canonical molecular changes in colorectal adenocarcinomas.
    Kim JC; Roh SA; Cho DH; Kim TW; Yoon SN; Kim CW; Yu CS; Kim SY; Kim YS
    Anticancer Res; 2009 Aug; 29(8):3115-23. PubMed ID: 19661324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant therapy of colorectal cancer: where do we stand?
    Macdonald JS
    Oncology (Williston Park); 1989 Jun; 3(6):87-92; discussion 93-6, 98. PubMed ID: 2701573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update on treatment advances for the first-line therapy of metastatic colorectal cancer.
    Lee JJ; Chu E
    Cancer J; 2007; 13(5):276-81. PubMed ID: 17921724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients.
    Sato Y; Fujiwara T; Mine T; Shomura H; Homma S; Maeda Y; Tokunaga N; Ikeda Y; Ishihara Y; Yamada A; Tanaka N; Itoh K; Harada M; Todo S
    Cancer Sci; 2007 Jul; 98(7):1113-9. PubMed ID: 17459063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TP53 mutation in colorectal cancer.
    Iacopetta B
    Hum Mutat; 2003 Mar; 21(3):271-6. PubMed ID: 12619112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.